Uncategorized
Enrollment begins for cataract surgery pain trial
Patient enrollment has begun in a phase III clinical trial of a low dose of bromfenac delivered via a
synthetic polymer-based formulation designed to extend the residence time of a drug (BromSite, InSite Vision) for
the reduction of pain and inflammation after cataract surgery.